Associations of Serum Butyrylcholinesterase Activity With Hepatic Steatosis and Liver Stiffness in U.S. Adults: NHANES 2021–2023

Abstract Background Serum butyrylcholinesterase (BChE) has been linked to metabolic dysfunction and hepatic steatosis. We examined associations of BChE activity and concentration with liver phenotypes and their incremental discriminatory value. Methods We analyzed 4,298 adults aged ≥ 20 years from NHANES 2021–2023 in a survey-weighted cross-sectional study. Multivariable regression assessed associations between serum BChE activity and controlled attenuation parameter (CAP), CAP-defined steatosis (≥ 274 dB/m), and liver stiffness measurement (LSM). Sensitivity analyses addressed metabolic adjustment, alternative steatosis definitions, and joint modeling of activity and concentration. Discrimination was evaluated beyond clinical risk factors. Results Per 1 survey-weighted standard deviation higher BChE activity, CAP was 8.90 dB/m higher (95% CI, 6.74–11.07), and steatosis prevalence was greater (prevalence ratio, 1.19; 95% CI, 1.14–1.23). Associations persisted across subgroups, alternative CAP thresholds, and a metabolic dysfunction-associated steatotic liver disease phenotype. Additional adjustment for HbA1c and lipids attenuated the CAP association (N = 4,218; β = 5.95 dB/m; 95% CI, 3.49–8.42). In a joint model (N = 4,297), activity remained associated with CAP after adjustment for concentration (β = 8.70; 95% CI, 4.45–12.95), whereas concentration showed little conditional association (β = 0.25; 95% CI, − 3.22 to 3.73). Adding activity beyond concentration increased weighted in-sample R² by 0.00578. Adding activity to clinical factors increased the area under the curve from 0.820 to 0.829 (difference, 0.009; 95% CI, 0.005–0.013). Adjusted LSM associations were not consistently significant, although exploratory spline analysis suggested nonlinearity. Conclusions Higher BChE activity was associated with CAP-measured hepatic steatosis, but added discrimination was modest. Cross-sectional findings do not establish causality or clinical utility.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-17
DOI
https://doi.org/10.21203/rs.3.rs-11753806/v1
Primary Topic
Liver Disease Diagnosis and Treatment
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Associations of Serum Butyrylcholinesterase Activity With Hepatic Steatosis and Liver Stiffness in U.S. Adults: NHANES 2021–2023

Elsayed Balbaa, Abdulrhman H.M. Muhaisen, Samah Rjoub, Wejdan Y. Alquran
1 links
Research Square
Liver Disease Diagnosis and Treatment
preprint

Associations of Serum Butyrylcholinesterase Activity With Hepatic Steatosis and Liver Stiffness in U.S. Adults: NHANES 2021–2023

Elsayed Balbaa, Abdulrhman H.M. Muhaisen, Samah Rjoub, Wejdan Y. Alquran
preprint en

Abstract

Abstract Background Serum butyrylcholinesterase (BChE) has been linked to metabolic dysfunction and hepatic steatosis. We examined associations of BChE activity and concentration with liver phenotypes and their incremental discriminatory value. Methods We analyzed 4,298 adults aged ≥ 20 years from NHANES 2021–2023 in a survey-weighted cross-sectional study. Multivariable regression assessed associations between serum BChE activity and controlled attenuation parameter (CAP), CAP-defined steatosis (≥ 274 dB/m), and liver stiffness measurement (LSM). Sensitivity analyses addressed metabolic adjustment, alternative steatosis definitions, and joint modeling of activity and concentration. Discrimination was evaluated beyond clinical risk factors. Results Per 1 survey-weighted standard deviation higher BChE activity, CAP was 8.90 dB/m higher (95% CI, 6.74–11.07), and steatosis prevalence was greater (prevalence ratio, 1.19; 95% CI, 1.14–1.23). Associations persisted across subgroups, alternative CAP thresholds, and a metabolic dysfunction-associated steatotic liver disease phenotype. Additional adjustment for HbA1c and lipids attenuated the CAP association (N = 4,218; β = 5.95 dB/m; 95% CI, 3.49–8.42). In a joint model (N = 4,297), activity remained associated with CAP after adjustment for concentration (β = 8.70; 95% CI, 4.45–12.95), whereas concentration showed little conditional association (β = 0.25; 95% CI, − 3.22 to 3.73). Adding activity beyond concentration increased weighted in-sample R² by 0.00578. Adding activity to clinical factors increased the area under the curve from 0.820 to 0.829 (difference, 0.009; 95% CI, 0.005–0.013). Adjusted LSM associations were not consistently significant, although exploratory spline analysis suggested nonlinearity. Conclusions Higher BChE activity was associated with CAP-measured hepatic steatosis, but added discrimination was modest. Cross-sectional findings do not establish causality or clinical utility.

Research Square
Alexandria University (EG), Yarmouk University (JO)
Good health and well-being
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon